These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 30643381

  • 21. Loteprednol etabonate gel 0.5% vs prednisolone acetate suspension 1% for the treatment of inflammation after cataract surgery in children.
    Vittitow JL, Williams JI.
    J Cataract Refract Surg; 2020 Aug; 46(8):1092-1101. PubMed ID: 32352250
    [Abstract] [Full Text] [Related]

  • 22. The role of KPI-121 0.25% in the treatment of dry eye disease: penetrating the mucus barrier to treat periodic flares.
    Gupta PK, Venkateswaran N.
    Ther Adv Ophthalmol; 2021 Aug; 13():25158414211012797. PubMed ID: 34017938
    [Abstract] [Full Text] [Related]

  • 23. Loteprednol etabonate suspension 0.2% administered QID compared with olopatadine solution 0.1% administered BID in the treatment of seasonal allergic conjunctivitis: a multicenter, randomized, investigator-masked, parallel group study in Chinese patients.
    Gong L, Sun X, Qu J, Wang L, Zhang M, Zhang H, Wang L, Gu Y, Elion-Mboussa A, Roy L, Zhu B.
    Clin Ther; 2012 Jun; 34(6):1259-1272.e1. PubMed ID: 22627057
    [Abstract] [Full Text] [Related]

  • 24. Bromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ocular pain and inflammation.
    Donnenfeld ED, Holland EJ, Stewart RH, Gow JA, Grillone LR, Bromfenac Ophthalmic Solution 0.09% (Xibrom) Study Group.
    Ophthalmology; 2007 Sep; 114(9):1653-62. PubMed ID: 17445902
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Topical ketorolac tromethamine 0.5% ophthalmic solution in ocular inflammation after cataract surgery.
    Solomon KD, Cheetham JK, DeGryse R, Brint SF, Rosenthal A.
    Ophthalmology; 2001 Feb; 108(2):331-7. PubMed ID: 11158809
    [Abstract] [Full Text] [Related]

  • 28. Dexamethasone Intracameral Drug-Delivery Suspension for Inflammation Associated with Cataract Surgery: A Randomized, Placebo-Controlled, Phase III Trial.
    Donnenfeld E, Holland E.
    Ophthalmology; 2018 Jun; 125(6):799-806. PubMed ID: 29397189
    [Abstract] [Full Text] [Related]

  • 29. Once daily dosing of bromfenac ophthalmic solution 0.09% for postoperative ocular inflammation and pain.
    Silverstein SM, Cable MG, Sadri E, Peace JH, Fong R, Chandler SP, Gow JA, Klier SM, McNamara TR, Bromfenac Ophthalmic Solution Once Daily (Bromday) Study Group.
    Curr Med Res Opin; 2011 Sep; 27(9):1693-703. PubMed ID: 21751945
    [Abstract] [Full Text] [Related]

  • 30. Besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis in adults and children.
    DeLeon J, Silverstein BE, Allaire C, Gearinger LS, Bateman KM, Morris TW, Comstock TL.
    Clin Drug Investig; 2012 May 01; 32(5):303-17. PubMed ID: 22420526
    [Abstract] [Full Text] [Related]

  • 31. Loteprednol etabonate 0.5% versus prednisolone acetate 1.0% for the treatment of inflammation after cataract surgery.
    Lane SS, Holland EJ.
    J Cataract Refract Surg; 2013 Feb 01; 39(2):168-73. PubMed ID: 23232255
    [Abstract] [Full Text] [Related]

  • 32. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. The Loteprednol Etabonate Giant Papillary Conjunctivitis Study Group I.
    Friedlaender MH, Howes J.
    Am J Ophthalmol; 1997 Apr 01; 123(4):455-64. PubMed ID: 9124242
    [Abstract] [Full Text] [Related]

  • 33. Multicenter randomized phase 3 study of a sustained-release intracanalicular dexamethasone insert for treatment of ocular inflammation and pain after cataract surgery.
    Tyson SL, Bafna S, Gira JP, Goldberg DF, Jones JJ, Jones MP, Kim JK, Martel JM, Nordlund ML, Piovanetti-Perez IK, Singh IP, Metzinger JL, Mulani D, Sane S, Talamo JH, Goldstein MH, Dextenza Study Group.
    J Cataract Refract Surg; 2019 Feb 01; 45(2):204-212. PubMed ID: 30367938
    [Abstract] [Full Text] [Related]

  • 34. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance.
    Pflugfelder SC, Maskin SL, Anderson B, Chodosh J, Holland EJ, De Paiva CS, Bartels SP, Micuda T, Proskin HM, Vogel R.
    Am J Ophthalmol; 2004 Sep 01; 138(3):444-57. PubMed ID: 15364229
    [Abstract] [Full Text] [Related]

  • 35. Difluprednate ophthalmic emulsion 0.05% (Durezol) administered two times daily for managing ocular inflammation and pain following cataract surgery.
    Smith S, Lorenz D, Peace J, McLeod K, Crockett RS, Vogel R.
    Clin Ophthalmol; 2010 Sep 07; 4():983-91. PubMed ID: 20856594
    [Abstract] [Full Text] [Related]

  • 36. 0.2% Betamethasone Sodium Phosphate: A Multicenter, Randomized, Double-Masked Study to Compare Its Ocular Safety, Tolerability, and Efficacy to Vehicle in Cataract Surgery Subjects.
    Hosseini K, Gollamudi S, Reiser H, Walters T, Lindstrom RL.
    Clin Ophthalmol; 2023 Sep 07; 17():2219-2230. PubMed ID: 37564159
    [Abstract] [Full Text] [Related]

  • 37. Safety and tolerability of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis: data from six clinical and phase I safety studies.
    Comstock TL, Paterno MR, Decory HH, Usner DW.
    Clin Drug Investig; 2010 Sep 07; 30(10):675-85. PubMed ID: 20629472
    [Abstract] [Full Text] [Related]

  • 38. Comparison of Efficacy of Difluprednate 0.05% and Loteprednol Gel 0.5% After Cataract Surgery.
    Abessi B, Brooksby L, Schultze RL.
    Eye Contact Lens; 2018 Nov 07; 44 Suppl 2():S37-S42. PubMed ID: 28628490
    [Abstract] [Full Text] [Related]

  • 39. Comparison of ketorolac tromethamine 0.5% and loteprednol etabonate 0.5% for inflammation after phacoemulsification: prospective randomized double-masked study.
    Holzer MP, Solomon KD, Sandoval HP, Vroman DT.
    J Cataract Refract Surg; 2002 Jan 07; 28(1):93-9. PubMed ID: 11777716
    [Abstract] [Full Text] [Related]

  • 40. The efficacy of bromfenac ophthalmic solution 0.07% dosed once daily in achieving zero-to-trace anterior chamber cell severity following cataract surgery.
    Silverstein SM, Jackson MA, Goldberg DF, Muñoz M.
    Clin Ophthalmol; 2014 Jan 07; 8():965-72. PubMed ID: 24876763
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.